Min Peng

The paper identifies THPO, IGF1, and MAPK as therapeutic targets for mitochondrial respiratory chain disease and osteosarcoma, showing their modulation can replicate the benefits of CHX treatment.

This paper develops a TPD platform using CAR T cells to degrade extracellular TNF, achieving disease remission in a rheumatoid arthritis model.

This study evaluates metabolic and mitochondria-targeted therapies for osteosarcoma using in vitro models, finding that combined treatments like ONC201/ONC206/metformin show enhanced cytotoxicity with minimal toxicity to normal cells.

This study identifies TMEM41B as an ER Ca2+ release channel that maintains T cell metabolic quiescence and responsiveness by regulating signaling pathways and receptor expression.

The paper investigates how FANCJ helicase affects PARP1 activity during DNA replication in BRCA1 deficient cells, revealing its role in PARPi efficacy and resistance.